Azaphilone Compounds Modulate Nuclear Hormone Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compositions and methods for modulating nuclear hormone receptor activity and treating diseases related to androgen activity are limited in efficacy and specificity, particularly in addressing over-activation of androgen receptors and 5α-reductase-related disorders.
Innovation Solution
The development of azaphilone compounds, such as monascuspiloin, which are derived from red yeast rice fermentation products of Monascus spp., are used to modulate nuclear hormone receptor activity and inhibit 5α-reductase, offering a potential therapeutic approach for conditions like prostate cancer and androgen-dependent alopecia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional compositions and methods are used to modulate nuclear hormone receptor activity, then the treatment can be administered, but the efficacy and specificity are limited
Solution Approach 1:
The patent modifies the chemical structure of azaphilone compounds by changing parameters such as substituting hydroxyl groups with alkoxy groups, introducing aromatic rings, and modifying side chains. These structural parameter changes result in compounds with improved binding affinity and specificity for nuclear hormone receptors, thereby resolving the contradiction between efficacy and specificity.
Solution Approach 2:
The patent creates composite molecular structures by combining different functional groups and structural motifs within the azaphilone framework. These composite structures enable the compounds to interact specifically with multiple nuclear hormone receptor subtypes, enhancing both efficacy and specificity simultaneously.
2Reliability
If conventional methods are used to treat androgen-related disorders, then treatment can be provided, but the IC50 values are higher indicating lower potency
Solution Approach 1:
The patent optimizes the molecular parameters of azaphilone compounds, including adjusting the length and saturation of side chains, modifying the core ring structure, and introducing hydrogen bond donors or acceptors. These parameter changes enhance the compound's binding affinity to androgen receptors, achieving lower IC50 values and thus higher potency.
3Reliability
If existing therapeutic approaches are used, then treatment can be administered, but the safety profiles are insufficient
Solution Approach 1:
The patent introduces functional groups with specific local chemical properties into the azaphilone structure, such as carboxylic acid groups for ionic bonding or aromatic rings for pi-pi stacking. These local quality modifications enable selective binding to target receptors while minimizing interactions with off-target proteins, thereby improving safety profiles and reducing adverse effects.
Data Source
AI summary
The present invention concerns the uses of an azaphilone compound of formula (I):formula (I):or a pharmaceutically acceptable derivative thereof as described in the specification for modulation of the activity of a nuclear hormone receptor and for prevention and/or treatment of a disease or disorder related to nuclear hormone receptor activity.